Synthesizing data? Who does that? Aren’t we supposed to be running the experiments and measuring things to produce real data? While generally true, there are scenarios in which the use of generative AI (GenAI) is beneficial. Let’s explore the benefits via “what if” scenarios. Before we begin, it’s important to
Rare diseases, often called orphan diseases, affect a small percentage of the population. Despite their rarity, these diseases collectively impact millions worldwide. Being a health care professional who cares deeply about overall patient care, the challenges in diagnosing and treating rare diseases resonate profoundly with me. Limited data availability, dispersed
The health care and life sciences market is accelerating – but not without a few necessary pitstops. Machine learning, digital twins, generative AI, robots as doctors, medications with sensors, and surgery at the speed of light. It’s all driving the market. Year after year, market researchers, analyst firms, and industry
The high cost of pricing myopia When launching a pharmaceutical product, it’s not enough to negotiate the best reimbursable price for each local market. Overall financial performance will depend on successfully managing go-to-market strategies at the global level. That means determining the optimal price and launch sequence for all the
The high cost of pricing myopia When launching a pharmaceutical product, it’s not enough to negotiate the best reimbursable price for each local market. Overall financial performance will depend on successfully managing go-to-market strategies at the global level. That means determining the optimal price and launch sequence for all the
For health and life sciences organizations, discussions about big data include gaining value from that data in the form of real-world evidence. Consider for a moment the amount of healthcare data that exists today thanks to the adoption of electronic health records. Then think about the future with data from
